急性髓系白血病患者白血病细胞CD34和CD38抗原的表达及其临床意义

doi:10.13481/j.1671-587x.20150231

Abstract

Abstract:

Objective To investigate the expressions of CD34 and CD38 antigens in the leukemia cells in the patients with firstly-diagnosed acute myeloid leukemia (AML) and their relationships with the prognosis,and to explore the role of the expressions of CD34 and CD38 antigens in predicting the prognosis of the AML patients.Methods The expressions of CD34 and CD38 antigens in the leukemia cells in 94 cases of AML patients were detected by flow cytometry. 36 patients with CD34⁺ CD38^- antigen and 58 patients with CD34⁺CD38⁺ antigen were identified by the expressions of CD38 and treated with IA Regimen. The complete remission rate (CRR),the relapse rate,the median overall survival (OS),the median disease free survival (DFS) and the survival rate of the patients in two groups were compared.Results There was no significant difference of the CRR of the patients between CD34⁺ CD38^- and CD34⁺CD38⁺ groups (77.8% vs 86.2%,P>0.05). However,the relapse rate and the 1-year relapse rate of the patients with CD34⁺ CD38^- antigen (53.8% and 36.0%) were higher than those of the patients with CD34⁺CD38⁺ antigen(27.0% and 14.3%)(P<0.05).The median OS and median DFS of the patients in CD34⁺ CD38^- group (13.60 months and 12.87 months) were shorter than those in CD34⁺CD38⁺ group (20.33 months and 33.93 months) (P<0.05).The 1-year and 2-year survival rates of the patients in CD34⁺ CD38^- group (52.8% and 38.9%) were lower than those in CD34⁺CD38⁺ group (75.9% and 48.3%)(P<0.05).Conclusion The expression of CD34⁺ CD38^- antigen in the leukemia cells offers a new prognostic factor for the AML patients. The expression of CD34⁺ CD38^- antigen predicts a worse prognosis in the AML patients.

Key words: CD34⁺ CD38^-, CD34⁺CD38⁺, acute myeloid leukemia, prognosis, idarubicin

CLC Number:

R733.7

WEI Shanshan, ZHOU Maohua, LI Jingao, CHEN Jing, CHEN Shaoxian, LI Qian, XIA Pingfang, PENG Qi, SHE Miaorong. Expressions of CD34 and CD38 antigens in leukemia cells of patients with acute myeloid leukemia and their clinical significances[J].Journal of Jilin University Medicine Edition, 2015, 41(02): 362-368.

References

[1] Peng HL,Zhang GS,Gong FJ,et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia:analysis of 147 patients[J]. Croat Med J,2008,49(5):650-669.

[2] Thiede C,Koch S,Creutzig E,et al. Prevalence and prognostic impact of NPM1 mutations in 1 485 adult patients with acute myeloid leukemia (AML)[J]. Blood,2006,107(10):4011-4020.

[3] Ruan M,Zhang L,Han C,et al. NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia[J]. Zhonghua Er Ke Za Zhi,2014,52(4):303-307.

[4] Barragan E,Cervera J,Bolufer P,et al. Prognostic implications of Wilms'tumor gene (WT1) expression in patients with de novo acute myeloid leukemia[J]. Haematologica,2004,89(8):926-933.

[5] Jourdan E,Boissel N,Chevret S,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia[J]. Blood,2013,121(12):2213-2223.

[6] Whitman SP,Maharry K,Radmacher MD,et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia:a cancer and leukemia group B study[J]. Blood,2010,116(18):3622-3626.

[7] Jones RJ,Matsui WH,Smith BD. Cancer stem cells:are we missing the target?[J]. J Natl Cancer Inst,2004,96(8):583-585.

[8] Huff CA,Matsui W,Smith BD,et al. The paradox of response and survival in cancer therapeutics[J]. Blood,2006,107(2):431-434.

[9] Lapidot T,Sirard C,Vormoor J,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature,1994,367(6464):645-648.

[10] Bonnet D,Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med,1997,3(7):730-737.

[11] Wang L,Gao L,Xu S,et al. FISH⁺CD34⁺ CD38^- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome[J]. J Hematol Oncol,2013,6(1):85.

[12] 张之南. 血液病诊断及疗效标准[M]. 2版. 北京:科学出版社,1998:168-218.

[13] Guzman ML,Neering SJ,Upchurch D,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood,2001,98(8):2301-2307.

[14] She M,Niu X,Chen X,et al. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity[J]. Cancer Lett,2012,318(2):173-179.

[15] Ebinger M,Witte KE,Ahlers J,et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia[J]. Leuk Res,2010,34(9):1139-1142.

[16] Long J,Liu S,Li K,et al. High proportion of CD34⁺/CD38^-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia[J]. Leuk Lymphoma,2014,55(3):611-617.

[17] Witte KE,Ahlers J,Schafer I,et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia[J]. Pediatr Hematol Oncol,2011,28(2):91-99.

[18] van Rhenen A,Feller N,Kelder A,et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival[J]. Clin Cancer Res,2005,11(18):6520-6527.

[19] Zhang CP,Wei H,Wang HJ,et al. Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2011,19(5):1268-1272.

[20] Leung W,Pui CH,Coustan-Smith E,et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia[J]. Blood,2012,120(2):468-472.

[21] Plesa A,Elhamri M,Clapisson G,et al. Higher percentage of CD34⁺ CD38^- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia[J]. Leuk Lymphoma,2014,17(7):1-8.

[22] Hoang VT,Zepeda-Moreno A,Ho AD. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance[J]. Biotechnol J,2012,7(6):779-788.

[23] Ravandi F,Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia[J]. Clin Cancer Res,2006,12(2):340-344.

Expressions of CD34 and CD38 antigens in leukemia cells of patients with acute myeloid leukemia and their clinical significances

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin. Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1047-1051.
[2]	ZHANG Tao, ZHANG Guoming, YAN Fei, LIU Zheng, HUO Qiang. Values of evaluation of heart rate variability in major adverse cardiac events in patients with acute myocardial infarction after PCI [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 780-785.
[3]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[4]	FAN Liwen, FU Tong, GU Lin, WU Di, JIA Hongyao, SONG Dong. Accessory breast cancer: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 412-415.
[5]	SUN Huiying, Du Bo, YU Zhi, LIU Hongquan, YU Hong. Clinical analysis on sudden sensorineural hearing loss complicated with BPPV and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1025-1029.
[6]	SU Junyan, LI Yingjin, XU Changyan. Influence of CD96 and CD71 expressions in surface of leukemia stem cells in therapeutic effects and prognosis of children with acute leukemia [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 776-781.
[7]	YANG Dongyang, LAI Xiaorong, LI Ying, MA Liyu, LUO Gang, LI Zijun, XU Fei, MA Dong. Influence of primary resection and KRAS gene mutation in prognosis of mild symptomatic patients with stage Ⅳ colorectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 805-811.
[8]	HAO Zheng, LIU Nan, WANG Lu, LI Dongyuan, ZHAO Conghai, LIU Weiming, CHEN Zhuo, ZHANG Jinnan. Comparison of clinical effects between hematoma aspiration surgery guided by stereotactic and simple positioning in treatment of patients with medium dose of hypertensive hemorrhage [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 130-134.
[9]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[10]	GU Sanwei, MA Hongshuang, ZHAO Ling, JIANG Zhenyu. Analysis on clinical characteristics of PM/DM combined with thyroid disease [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 999-1004.
[11]	DING Xianfei, ZHOU Xueliang, DOU Mengmeng, LI Lifeng, GUO Lina, WANG Feng, FAN Qingxia. Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 783-788.
[12]	LI Qian, LI Jingao, ZHOU Maohua, LIAO Pengjun, PENG Qi, CHEN Jing, CHEN Shaoxian, WEI Shanshan, HUANG Huiting, SHE Miaorong. Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 283-289.
[13]	ZAO Hang, WANG XU, LI WEI. Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 316-320.
[14]	SHAO Wanting, FU Tong, WU Panpan, WU Di, LI Sijie, ZHENG Chao, FAN Zhimin. Evaluation on efficacy of trastuzumab combined with neoadjuvant chemotherapy in Her-2 positive breast cancer patients and analysis of influencing factors of prognosis [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 351-357.
[15]	ZHANG Heng, QIN Zhigang, LIANG Huaxin, FANG Xiaoxuan. Influence of delayed traumatic intracranial hemorrhage followed by large decompressive craniectomy in prognosis of patients with severe traumatic brain injury [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 362-365.